1Hoekstra M,Haagsma C,Neef C,et al.Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.J Rheumatol,2004,31:645-648.
2Braun J,K(a)stner P,Flaxenberg P,et al.Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis:results of a six-month,multicenter,randomized,double-blind,controlled,phase Ⅳ trial.Arthritis Rheum,2008,58:73-81.
3Linde L,Hetland ML,Ostergaard M.Drug survival and reasons for discontinuation of intramuscular methotrexate:a study of 212 consecutive patients switching from oral methotrexate.Scand J Rheumatol,2006,35:102-106.
4Wegrzyn J,Adeleine P,Miossec P.Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis.Ann Rheum Dis,2004,63:1232-1234.
5Bakker MF,Jacobs JW,Welsing PM,et al.Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis.? A post hoc analysis of the CAMERA study.Ann Rheum Dis,2010,Epub ahead of print.
6Bharadwaj A,Agrawal S,Batley M,et al.Use of parenteral methotrexate significantly reduces the need for biological therapy.Rheu matology,2008,47:222.
7Salliot C,van der Heijde D.Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis:a systematic literature research.Ann Rheum Dis,2009,68:1100-1104.
8Huber AM,Giannini EH,Bowyer SL,et al.Protocols for the initial treatment of moderately severe juvenile dermatomyositis:results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.Arthritis Care Res (Hoboken),2010,62:219-225.
9Müller-Ladner U,Rockwitz K,Brandt-Jürgens J,et al.Tolerability and Patient/Physician Satisfaction with Subcutaneously Administered Methotrexate Provided in Two Formulations of Different Drug Concentrations in Patients with Rheumatoid Arthritis.Open Rheumatol J,2010,4:15-22.
8Braun J, K:istner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial [J]. Arthritis Rheum, 2008, 58 (1) : 73-81.
9Bakker MF, Jacobs JW, Welsing PM, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study [J]. Ann Rheum Dis, 2010, 69(10) : 1849-1852.
10Shoda H, Inokuma S, Yajima N, et al. Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients [J]. Mod Rheumatol, 2007, 17 (4) : 311-316.
